Therapeutic use of interferon-? for lymphomatoid papulosis

Lymphomatoid Papulosis Followed by Pityriasis Lichenoides: A Common Pathogenesis?

“…If this hypothesis can be confirmed, therapies that promote Th1 responses such as interferon alfa or gamma might be useful in some patients with LyP. 73,75 Our case seems to be unique in that LyP-B seems to have preceded a diagnosis of PL. Although the association of 2 uncommon conditions in the same individual due to chance cannot be excluded, an alternative explanation must be considered.…”

EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*

“…76,80,88,[91][92][93][94][95] CR was observed in 4 of 5 patients after 2-6 weeks of treatment with 3-15 MU IFN-␣ per week in an open trial. 94 Discontinuation resulted in relapses within 3-4 weeks and the necessity for maintenance therapy over 10-17 months. 94 Recent experimental data suggest that combined use of MTX and IFN-␣ could be useful in LYP.…”

“…94 Discontinuation resulted in relapses within 3-4 weeks and the necessity for maintenance therapy over 10-17 months. 94 Recent experimental data suggest that combined use of MTX and IFN-␣ could be useful in LYP. 96 Despite that expression of Toll-like receptors has been demonstrated in CD30 ϩ LPDs, the Toll-like receptor agonist imiquimod was reported only in 1 patient with CR, in whom all treated lesions resolved within 2 weeks.…”

Practical Management of CD30+ Lymphoproliferative Disorders

“…The other 3 patients were treated for longer 12-to 13-month intervals with IFN and were able to maintain their remission throughout the follow-up period after drug discontinuation (from 1 to 11 years) and did not require any retreatment, suggesting that treating with IFN for at least 1 year may yield better long-term results. 32 Intralesional IFN has been used successfully for larger, more refractory lesions. One report described 1 MU intralesional injection of IFN-a2b into 3 LyP lesions (3 MU total) 3 times weekly.…”